The global professional services firm reported sustained organic revenue growth and margin expansion for 2025, backed by its '3x3' strategic plan and technology investments. Leadership provided an upbeat outlook for 2026, targeting continued mid-single-digit growth and further profitability gains.
Chevron Corp. reported a drop in fourth-quarter earnings that nonetheless beat analyst expectations, as the oil giant emphasized operational efficiency to navigate lower crude prices. The company, the sole U.S. producer active in Venezuela, signaled it is assessing further investment opportunities in the country following recent geopolitical shifts.
The German sportswear giant reports preliminary figures showing robust growth for the Adidas brand, driven by double-digit expansion across all regions, and unveils a major capital return program to shareholders.
From a record-breaking public health crisis in South Carolina to a stunning archaeological find in Mexico, here are the major developments you need to know this afternoon, alongside a look at how global politics is reshaping daily life from Havana to your local coffee shop.
The Horatio Alger Award bestowed upon ResMed founder Dr. Peter Farrell underscores the company's decades-long leadership in sleep and respiratory care, bringing its financial performance and competitive strategy into sharper focus for investors.
A quirk in the UK tax system means those earning between £100,000 and £125,140 face an effective 60% marginal tax rate, while also losing crucial childcare benefits. We examine the growing trap and the financial planning strategies to navigate it.
ResMed reports robust revenue and margin expansion in its fiscal Q2 2026, driven by strong device and mask sales. Management highlights strategic investments in AI-powered patient tools and views GLP-1 medications as a potential catalyst for future demand.
Despite a challenging year marked by oil price volatility and softer demand for completion services, Liberty Energy (LBRT) closed 2025 with a resilient Q4 performance. The company is aggressively scaling its distributed power solutions business, targeting 3 GW of projects by 2029, even as it manages pricing pressures in its core fracking operations.
GSK makes a dual strategic move, acquiring RAPT Therapeutics for its food allergy portfolio and securing broader European approval for its RSV vaccine Arexvy, reinforcing its focus on immunology and respiratory health.
Arthur J. Gallagher & Co. reported robust fourth-quarter results, driven by a potent mix of organic expansion and strategic acquisitions like AssuredPartners. Management projects sustained mid-single-digit growth for 2026, backed by a significant capital reserve for further mergers and acquisitions.
Amidst market volatility, EVERTEC Inc. (EVTC) presents a compelling investment case. Trading at depressed valuation multiples, the Latin American transaction processing leader combines a 'boring but consistent' operational profile with significant potential for multiple expansion and steady growth, offering a unique risk/reward balance for patient investors.
Bio-Techne (TECH) gains market attention with the launch of its Cultrex Synthetic Hydrogel, a key innovation for 3D cell research. While the product debut coincides with recent share price strength, longer-term returns tell a more complex story for investors.
Johnson & Johnson's oncology portfolio gains momentum with new clinical data for prostate cancer drug Erleada and a broader FDA label for multiple myeloma therapy Darzalex Faspro, reinforcing its competitive stance in key cancer markets.
Chinese EV maker NIO Inc. is hitting new operational highs, reporting record quarterly deliveries and improving margins as its multi-brand strategy gains traction. With a strengthened balance sheet and a global expansion underway, analysts debate whether the company is nearing a crucial inflection point.
Amid a cautious retail environment, Ollie's Bargain Outlet (OLLI) is posting impressive growth by leaning into aggressive pricing and rapid store expansion. Its latest earnings beat and a fortified loyalty program are painting a compelling picture for long-term investors, even as valuation questions linger.
Avery Dennison (AVY), the often-overlooked materials science giant, is drawing investor attention with its pivot to high-margin digital identification solutions and a rock-solid financial profile. With intelligent labels driving growth and a dividend that has increased for 15 consecutive years, the company presents a case for resilient, innovation-led expansion.
ResMed Inc., the sleep therapy giant, faces a pivotal moment. While benefiting from a competitor's recall and a growing market funnel, emerging oral treatments and shifting dynamics pose fresh challenges to its long-held CPAP business model.
Amid a volatile market, specialty insurer Palomar Holdings (PLMR) presents a compelling growth story. With a disciplined underwriting strategy, robust risk management, and a track record of doubling profits every few years, the company trades at multiples that may significantly undervalue its consistent execution and expansion potential.
SiTime Corporation (NASDAQ: SITM), a leader in MEMS-based timing solutions, is attracting bullish attention as its technology becomes increasingly critical for AI infrastructure and high-performance computing. With strong recent financials and strategic expansion, the company is navigating both opportunities and risks in a complex semiconductor landscape.
Personalis, Inc. (NASDAQ: PSNL) is attracting investor attention with its ultra-sensitive NeXT Personal blood test, capable of detecting cancer recurrence far earlier than standard methods. With a key distribution deal and anticipated Medicare reimbursement, the company could be on the cusp of a significant inflection point.
